Financing
Debt Issuance Proceeds
Moderna Debt Issuance Proceeds remained flat by 0.0% to $150M in Q4 2025 compared to the prior quarter.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryLeverage
SignalContext dependent
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025Feb 20, 2026
How to read this metric
Higher proceeds indicate successful access to credit markets, potentially to fund R&D or infrastructure, but also increase future interest obligations.
Detailed definition
Cash proceeds received from the issuance of short-term or long-term debt instruments, such as bonds or credit facility d...
Peer comparison
Commonly used by mature biotech companies to supplement cash reserves without diluting existing shareholders.
Metric ID:
debt_issuanceHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $0 | $0 | $600M |
Range$0 – $600M
Debt Issuance Proceeds at Other Companies
Frequently Asked Questions
- What is Moderna's debt issuance proceeds?
- Moderna (MRNA) reported debt issuance proceeds of $150M in Q4 2025.
- What does debt issuance proceeds mean?
- Cash received from borrowing money through debt.